This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amarantus BioSciences Retains JS Barkats In New York As Corporate & Securities Counsel

SUNNYVALE, Calif. and NEW YORK, Oct. 15, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), today announced that it has retained the legal services of JS Barkats, PLLC  ("JS Barkats") to represent the  Company as its corporate and securities counsel. Going forward, JSBarkats will represent the Company on all corporate, securities, capital markets, divestitures, partnerships, sponsorships and regulatory compliance matters. Amarantus will continue to work with Wilson, Sonsini, Goodrich & Rosati, LLP for all MANF intellectual property matters, and with Foley & Lardner, LLP on all diagnostic intellectual property matters.

"We are excited to represent Amarantus and be given the opportunity to bring value-added services to the table for our new client. Our team of experienced attorneys is impressed with the Company's proprietary technology and approach to treating Parkinson's disease and Traumatic Brain Injury," said Sunny Joseph Barkats, Founding Partner at JS Barkats. "Amarantus' corporate awareness programs, through its #C4CT concussion program and emerging relationships with professional athletes, are pioneering within development-stage biotechnology that will allow the Company to carve out a unique position for itself in the marketplace as it executes on its business strategy."

Robert Rash, the co-managing partner of the Firm in the Alabama offices added "As a CPA and a securities attorney, I am very interested in Amarantus revenue model being prosecuted through the aggregation and partnering of the Parkinson's NuroPro blood test and Alzheimer's LymPro blood test. JSBarkats believes this Company has extremely bright, talented people on its management team and the business approach is unique and innovative. Hence, we are delighted to represent Amarantus in order to assist management in maximizing the Company's value for shareholders."

About JSBarkats, PLLC:

JS Barkats, a boutique law firm headquartered in the heart of midtown- Manhattan in New York, has an experienced team of 22 attorneys with satellite offices in Alabama, Florida and Israel, as well as international affiliated offices. The firm specializes in, IPO's, APO's for public companies, SEC compliance and representation, intellectual property, licensing, corporate partnerships, tax law, commercial and securities litigation, entertainment and brand awareness.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs